Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhong Ji Longevity Science Group PB Ratio?
Zhong Ji Longevity Science GroupHKSE:00767 -5.26%55 PB Ratio is 0.58 as of Aug. 12, 2026, which is 49% above its 10-year median of 0.39. GuruFocus rates HKSE:00767 with a GF Score™ of 55/100 and a GF Value™ of HK$0.89 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Zhong Ji Longevity Science Group ranks better than 92.27% on this metric.
HKSE:00767'
s PB Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.39 Max: 8.57
Current: 0.58
During the past 13 years, Zhong Ji Longevity Science Group's highest PB Ratio was 8.57. The lowest was 0.05. And the median was 0.39.
HKSE:00767's PB Ratio is ranked better than 92.27% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21
vs HKSE:00767: 0.58
During the past 12 months, Zhong Ji Longevity Science Group's average Book Value Per Share Growth Rate was -8.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -12.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -29.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhong Ji Longevity Science Group was 43.30% per year. The lowest was -75.70% per year. And the median was -27.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhong Ji Longevity Science Group PB Ratio Related Terms
Zhong Ji Longevity Science Group PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Zhong Ji Longevity Science Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhong Ji Longevity Science Group PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Zhong Ji Longevity Science Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhong Ji Longevity Science Group's PB Ratio falls into.
Zhong Ji Longevity Science Group PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhong Ji Longevity Science Group (HKSE:00767) has a PB Ratio of 0.58 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhong Ji Longevity Science Group and its competitors. This is 49% above median its historical median of 0.39. Over the past decade, Zhong Ji Longevity Science Group's PB Ratio has ranged from 0.05 to 8.57. According to the industry distribution chart, Zhong Ji Longevity Science Group ranks #15 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 7.7%.
Is Zhong Ji Longevity Science Group's PB Ratio too high?
Zhong Ji Longevity Science Group's current PB Ratio of 0.58 is 49% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 8.57. The Medical Diagnostics & Research industry median PB Ratio is 2.21. Zhong Ji Longevity Science Group's value of 0.58 is 73.8% below this industry median. Based on the distribution chart, Zhong Ji Longevity Science Group ranks #15 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Zhong Ji Longevity Science Group has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhong Ji Longevity Science Group's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Zhong Ji Longevity Science Group ranks #15 out of 194 companies for PB Ratio. This places Zhong Ji Longevity Science Group in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.21. Zhong Ji Longevity Science Group's value of 0.58 is 73.8% below this benchmark. Historically, Zhong Ji Longevity Science Group's own PB Ratio has ranged from 0.05 to 8.57 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 2.21, Zhong Ji Longevity Science Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.21, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhong Ji Longevity Science Group's current PB Ratio of 0.58 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhong Ji Longevity Science Group and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhong Ji Longevity Science Group's current PB Ratio is 0.58, which is 49% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhong Ji Longevity Science Group stock overvalued right now?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group (HKSE:00767) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.89, compared to a current price of HK$0.36 — trading 59.6% below its estimated fair value. The current PB Ratio is 0.58, which is 49% above median its 10-year median of 0.39 and 73.8% below the Medical Diagnostics & Research industry median of 2.21. Zhong Ji Longevity Science Group's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhong Ji Longevity Science Group (HKSE:00767), the current PB Ratio is 0.58 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhong Ji Longevity Science Group (HKSE:00767) Overvalued in 2026?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group stock appears to be undervalued.
The current stock price of HK$0.36 is trading 59.6% below its estimated GF Value™ of HK$0.89.
GuruFocus considers Zhong Ji Longevity Science Group to be Possible Value Trap.
Key valuation signals for HKSE:00767:
PB Ratio: 0.58 (49% above median its 10-year median of 0.39)
GF Value™: HK$0.89 vs. price of HK$0.36 (59.6% below fair value)
Industry Position: 73.8% below the Medical Diagnostics & Research median (#15 of 194)
No single metric tells the full story. See the HKSE:00767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhong Ji Longevity Science Group Ltd is an investment holding company. Through its subsidiaries, it engages in Longevity science business, Money lending and Financial Advisory, Securities and other investments, and Property investment. The company generates the majority of its revenue from the Longevity Science business. The Longevity science business includes the provision of diagnostic consultation, health and medical testing and checking, distribution of cancer prevention & immunity healthcare supplements, and the sales and distribution of longevity wine.
55GF Score
Get the complete analysis for HKSE:00767
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00767 has been successfully added to your 
